Editas Medicine develops CRISPR-based gene editing medicines for serious diseases from Cambridge, Massachusetts. It last closed at $1.82 on Nov 17, down 2.41% on the day. The average 12-month price target from 2 analysts is $5.50 (+201.4% from the last close), with a high of $6.00 and a low of $5.00. In the past 30 days there were 1 dark pool print totaling $790K, the largest $790K.
Only 2 firms rated EDIT in the past 90 days, not enough for a consensus
Average 12-month target
$5.50
▲ 201.4% upside
Based on 2 analysts who set a price target on EDIT in the past 90 days. The average target is $5.50, with a high of $6.00 and a low of $5.00, compared with the last close of $1.82.
Low $5.00Avg $5.50High $6.00
Blue marker: last close $1.82
Highest target$6.00
Average target$5.50
Lowest target$5.00
Latest rating changes
Wells FargoUpgrade
Oct 8Buy$6
GuggenheimUpgrade
Sep 23Buy$5
Ladenburg ThalmannInitiated
Aug 18Buy$6
Date
Firm
Action
Rating
Price target
Oct 8
Wells Fargo
Upgrade
Buy
$6
Sep 23
Guggenheim
Upgrade
Buy
$5
Aug 18
Ladenburg Thalmann
Initiated
Buy
$6
Loading…
Technical Analysis
EDIT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 36% below its 20 day and 41% below its 50 day average. It is 48% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $1.78, and the nearest resistance the Pivot at $1.86.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 12.3%/day
Key levels
$3.9452 week high+116.5%
$2.80100 day average+53.8%
$2.70200 day average+48.4%
$2.67Swing high (Oct 20)+46.7%
$2.5850 day average+41.8%
$2.4820 day average+36.3%
$1.90Pivot R1+4.4%
$1.86Pivot+2.2%
$1.82Last close
$1.78Pivot S1−2.2%
$1.6652 week low−8.8%
Indicators
RSI (14)
31.90
Weak, oversold below 30
Neutral
MACD
-0.16
Below its signal line
Bearish
Stochastic
5.8
Near the bottom of its range
Oversold
ADX (14)
14.1
No clear trend
Williams %R
-99.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-200.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−29.8%
Change over 10 sessions
Bearish
ATR (14)
$0.22
Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 28.3%/day
Key levels
$3.9452 week high+116.5%
$2.80100 day average+53.8%
$2.70200 day average+48.4%
$2.67Swing high (Oct 20)+46.7%
$2.5850 day average+41.8%
$2.4820 day average+36.3%
$1.90Pivot R1+4.4%
$1.86Pivot+2.2%
$1.82Last close
$1.78Pivot S1−2.2%
$1.6652 week low−8.8%
Indicators
RSI (14)
37.90
Weak, oversold below 30
Neutral
MACD
-0.14
Below its signal line
Bearish
Stochastic
12.0
Near the bottom of its range
Oversold
ADX (14)
31.0
Trending up
Williams %R
-99.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-238.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−32.4%
Change over 10 sessions
Bearish
ATR (14)
$0.52
Typical daily range, 28.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for EDIT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how EDIT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow EDIT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How EDIT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EDIT is in one of them and how their past EDIT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Editas Medicine
Editas Medicine is a gene editing company based in Cambridge, Massachusetts. It develops medicines that use CRISPR technology to edit DNA inside the body, aiming to treat serious diseases, and its lead experimental candidate targets high cholesterol. The company also licenses its gene editing technology to partners such as Bristol Myers Squibb and Vertex Pharmaceuticals, which use it for medicines in other therapeutic areas.